Krystal Biotech, Inc. KRYS Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s additional paid-in capital?
- Krystal Biotech, Inc. (KRYS) reported additional paid-in capital of $1.2B in Q1 2026.
- How has Krystal Biotech, Inc.'s additional paid-in capital changed year-over-year?
- Krystal Biotech, Inc.'s additional paid-in capital increased by 6.1% year-over-year, from $1.13B to $1.2B.
- What is the long-term trend for Krystal Biotech, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s additional paid-in capital has grown at a 26.9% compound annual growth rate (CAGR), from $363.29M to $1.19B.
- What does additional paid-in capital mean?
- The amount of money shareholders paid for stock above its nominal par value.
- How do you interpret additional paid-in capital?
- An increase indicates successful equity capital raises, which are common for funding R&D and clinical trials in biotech.
- How does additional paid-in capital compare across companies?
- High for growth-stage biotech companies that rely on secondary offerings to fund research pipelines.